Pancreatic Cancer Research

ResearcherCedars-Sinai Medical CenterActive in the last 2 years

Veronica Placencio-Hickok

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5048145699. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper

Papers 9

  1. Fecal Microbiome Composition and Plasma Metabolomics in Pancreatic Cancer Cachexia Treated with Nutritional Support Co-author DOI 10.20944/preprints202401.0727.v1↗
  2. Plasma Metabolomics Predicts Chemotherapy Response in Advanced Pancreatic Cancer. Co-author DOI 10.3390/cancers15113020↗
  3. Hyaluronan heterogeneity in pancreatic ductal adenocarcinoma: Primary tumors compared to sites of metastasis. Co-author DOI 10.1016/j.pan.2021.09.015↗
  4. Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.6004/jnccn.2022.7039↗
  5. Feasibility and efficacy of enteral tube feeding on weight stability, lean body mass, and patient-reported outcomes in pancreatic cancer cachexia. First author DOI 10.1002/jcsm.12799↗
  6. Fecal elastase, an assay for exocrine pancreatic insufficiency, has clinical utility in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/1756284820964319↗
  7. Priority Rankings of Patient-Reported Outcomes for Pancreatic Ductal Adenocarcinoma: A Comparison of Patient and Physician Perspectives. Co-author DOI 10.6004/jnccn.2020.7548↗
  8. Treatment strategies and clinical outcomes of locally advanced pancreatic cancer patients treated at high-volume facilities and academic centers. Co-author DOI 10.1016/j.adro.2018.10.006↗
  9. A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2018.12.060↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrew Eugene Hendifar · 9 shared papers, 2019–2024 · strength 1.23
  2. Jun Gong · 7 shared papers, 2020–2024 · strength 1.04
  3. Arsen Osipov · 6 shared papers, 2019–2024 · strength 0.86
  4. Natalie Moshayedi · 4 shared papers, 2022–2024 · strength 0.67
  5. Stephen Jacob Pandol · 3 shared papers, 2021–2023 · strength 0.42
  6. Michelle Guan · 3 shared papers, 2020–2022 · strength 0.39
  7. Neil A. Bhowmick · 2 shared papers, 2023–2024 · strength 0.37
  8. Hayato Muranaka · 2 shared papers, 2023–2024 · strength 0.37
  9. Simon K. Lo · 3 shared papers, 2019–2022 · strength 0.33
  10. Nicholas N. Nissen · 3 shared papers, 2019–2022 · strength 0.33
  11. Gillian K. Gresham · 2 shared papers, 2020–2021 · strength 0.23
  12. Richard Tuli · 2 shared papers, 2019 · strength 0.19
  13. Nicholas P. Tatonetti · 1 shared paper, 2023 · strength 0.17
  14. Camille Ng · 1 shared paper, 2022 · strength 0.16
  15. Brent K. Larson · 1 shared paper, 2022 · strength 0.14
  16. Maria Q. B. Petzel · 1 shared paper, 2020 · strength 0.13
  17. Christopher E Forsmark · 1 shared paper, 2020 · strength 0.13
  18. John David · 1 shared paper, 2019 · strength 0.11
  19. Samuel Jacob Klempner · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.